InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
ANZ
2.59%
$32.45
ANZ GROUP HOLDINGS LIMITED - Corporate Spotlight
Market Cap $94.19B
!
Add to my watchlist
Reach your audience today.